Sentences with phrase «targeting epidermal»

Researchers found that a combination of drugs — one targeting epidermal growth factor receptor (EGFR) and one targeting tumor necrosis factor (TNF)-- effectively blocks the cancer from using TNF as an escape route.

Clinically important findings suggest that targeting the epidermal growth factor receptor (EGFR) and the fibroblast growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease, according to the study published today in the journal PLOS Genetics.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

Not exact matches

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

Triple - negative cancers are so called because they do not express receptors for the hormones estrogen and progesterone, nor for HER2 (human epidermal growth factor 2), and hence patients with these cancers are not candidates for treatment with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells.

Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy - refractory, advanced colorectal cancer.

In addition to RIPK2 binding as part of this computer - based (initial) screening, we selected compounds that inhibited epidermal growth factor receptor (IC50 values > 1000 nM; weak inhibitory activity) along with weak binding interactions in the EGFR and c - ABL binding sites, two common off - targets for previously identified RIPK2 inhibitors.

The other grant goes to Sheila Torres, BS, DVM, MS, PhD, DACVD, and Lucy Vulchanova, BS, PhD, of the University of Minnesota College of Veterinary Medicine, for their proposal titled, «A new drug target for improved epidermal barrier function in atopic dermatitis.»